Literature DB >> 26380766

Identification of immunohistochemical markers for distinguishing lung adenocarcinoma from squamous cell carcinoma.

Cheng Zhan1, Li Yan1, Lin Wang1, Yang Sun1, Xingxing Wang1, Zongwu Lin1, Yongxing Zhang1, Yu Shi1, Wei Jiang1, Qun Wang1.   

Abstract

BACKGROUND: Immunohistochemical staining has been widely used in distinguishing lung adenocarcinoma (LUAD) from lung squamous cell carcinoma (LUSC), which is of vital importance for the diagnosis and treatment of lung cancer. Due to the lack of a comprehensive analysis of different lung cancer subtypes, there may still be undiscovered markers with higher diagnostic accuracy.
METHODS: Herein first, we systematically analyzed high-throughput data obtained from The Cancer Genome Atlas (TCGA) database. Combining differently expressed gene screening and receiver operating characteristic (ROC) curve analysis, we attempted to identify the genes which might be suitable as immunohistochemical markers in distinguishing LUAD from LUSC. Then we detected the expression of six of these genes (MLPH, TMC5, SFTA3, DSG3, DSC3 and CALML3) in lung cancer sections using immunohistochemical staining.
RESULTS: A number of genes were identified as candidate immunohistochemical markers with high sensitivity and specificity in distinguishing LUAD from LUSC. Then the staining results confirmed the potentials of the six genes (MLPH, TMC5, SFTA3, DSG3, DSC3 and CALML3) in distinguishing LUAD from LUSC, and their sensitivity and specificity were not less than many commonly used markers.
CONCLUSIONS: The results revealed that the six genes (MLPH, TMC5, SFTA3, DSG3, DSC3 and CALML3) might be suitable markers in distinguishing LUAD from LUSC, and also validated the feasibility of our methods for identification of candidate markers from high-throughput data.

Entities:  

Keywords:  Lung cancer; The Cancer Genome Atlas (TCGA); immunohistochemical marker; receiver operating characteristic (ROC) curve analysis

Year:  2015        PMID: 26380766      PMCID: PMC4561256          DOI: 10.3978/j.issn.2072-1439.2015.07.25

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  26 in total

Review 1.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

2.  Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma.

Authors:  Zaur Hamidov; Annelore Altendorf-Hofmann; Yuan Chen; Utz Settmacher; Iver Petersen; Thomas Knösel
Journal:  J Clin Pathol       Date:  2011-07-01       Impact factor: 3.411

3.  Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.

Authors:  Koji Tsuta; Yuko Tanabe; Akihiko Yoshida; Fumiaki Takahashi; Akiko M Maeshima; Hisao Asamura; Hitoshi Tsuda
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

4.  Heterogeneous and abnormal localization of desmosomal proteins in oral intraepithelial neoplasms.

Authors:  Sohichi Aizawa; Takanaga Ochiai; Toshiaki Ara; Haruki Yamada; Hiromasa Hasegawa
Journal:  J Oral Sci       Date:  2014-09       Impact factor: 1.556

5.  Expression of desmogleins 1-3 and their clinical impacts on human lung cancer.

Authors:  Friederike Saaber; Yuan Chen; Tiantian Cui; Linlin Yang; Masoud Mireskandari; Iver Petersen
Journal:  Pathol Res Pract       Date:  2014-10-31       Impact factor: 3.250

6.  Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens.

Authors:  Said Khayyata; Shine Yun; Theresa Pasha; Bo Jian; Cindy McGrath; Gordon Yu; Prabodh Gupta; Zubair Baloch
Journal:  Diagn Cytopathol       Date:  2009-03       Impact factor: 1.582

7.  A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.

Authors:  Brian Z Ring; Robert S Seitz; Rodney A Beck; William J Shasteen; Alex Soltermann; Stefanie Arbogast; Francisco Robert; Marshall T Schreeder; Douglas T Ross
Journal:  Mod Pathol       Date:  2009-05-08       Impact factor: 7.842

8.  Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens.

Authors:  Aylin Simsir; Xiao-Jun Wei; Herman Yee; Andre Moreira; Joan Cangiarella
Journal:  Am J Clin Pathol       Date:  2004-03       Impact factor: 2.493

9.  The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer.

Authors:  Tiantian Cui; Yuan Chen; Linlin Yang; Thomas Knösel; Otmar Huber; Manuela Pacyna-Gengelbach; Iver Petersen
Journal:  Carcinogenesis       Date:  2012-08-31       Impact factor: 4.944

10.  Regulation of Desmocollin3 Expression by Promoter Hypermethylation is Associated with Advanced Esophageal Adenocarcinomas.

Authors:  Qinggang Wang; DunFa Peng; Shoumin Zhu; Zheng Chen; TianLing Hu; Mohammed Soutto; Rama Saad; Shutian Zhang; Wael Ei-Rifai
Journal:  J Cancer       Date:  2014-05-14       Impact factor: 4.207

View more
  28 in total

1.  AGTR1 promoter hypermethylation in lung squamous cell carcinoma but not in lung adenocarcinoma.

Authors:  Ruhua Chen; Qingxiao Hong; Jianzhong Jiang; Xiaoying Chen; Zhenhuan Jiang; Jinzhi Wang; Shunlin Liu; Shiwei Duan; Shunbin Shi
Journal:  Oncol Lett       Date:  2017-08-25       Impact factor: 2.967

2.  Knockdown of Immature Colon Carcinoma Transcript 1 Inhibits Proliferation and Promotes Apoptosis of Non-Small Cell Lung Cancer Cells.

Authors:  Yiling Wang; Jiantao He; Shenghui Zhang; Qingbo Yang; Bo Wang; Zhiyu Liu; Xintian Wu
Journal:  Technol Cancer Res Treat       Date:  2016-07-13

3.  E2F1-mediated repression of WNT5A expression promotes brain metastasis dependent on the ERK1/2 pathway in EGFR-mutant non-small cell lung cancer.

Authors:  Huanhuan Li; Fan Tong; Rui Meng; Ling Peng; Jiaojiao Wang; Ruiguang Zhang; Xiaorong Dong
Journal:  Cell Mol Life Sci       Date:  2020-10-19       Impact factor: 9.261

4.  An 8-Gene Signature for Classifying Major Subtypes of Non-Small-Cell Lung Cancer.

Authors:  Mehdi Hamaneh; Yi-Kuo Yu
Journal:  Cancer Inform       Date:  2022-06-14

5.  Mutations and expression of the NFE2L2/KEAP1/CUL3 pathway in Chinese patients with lung squamous cell carcinoma.

Authors:  Yongxing Zhang; Hong Fan; Shuo Fang; Lin Wang; Li Chen; Yulin Jin; Wei Jiang; Zongwu Lin; Yu Shi; Cheng Zhan; Qun Wang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

6.  The value of AGR2 and KRT5 as an immunomarker combination in distinguishing lung squamous cell carcinoma from adenocarcinoma.

Authors:  Bo Pan; Zi-Xin Wei; Ju-Xuan Zhang; Xin Li; Qing-Wei Meng; Ying-Yue Cao; Li-Shuang Qi; Yan Yu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

7.  Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.

Authors:  Peng Cao; Sanlan Wu; Wei Guo; Qilin Zhang; Weijing Gong; Qiang Li; Rui Zhang; Xiaorong Dong; Shuangbing Xu; Yani Liu; Shaojun Shi; Yifei Huang; Yu Zhang
Journal:  Metabolomics       Date:  2021-11-03       Impact factor: 4.290

8.  Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.

Authors:  Mengnan Zhao; Cheng Zhan; Ming Li; Xiaodong Yang; Xinyu Yang; Yong Zhang; Miao Lin; Yifeng Xia; Mingxiang Feng; Qun Wang
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.

Authors:  Joe W Chen; Joseph Dhahbi
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

10.  The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.

Authors:  Yicheng Liang; Yangyang Lei; Minjun Du; Mei Liang; Zixu Liu; Xingkai Li; Yushun Gao
Journal:  J Cell Mol Med       Date:  2021-06-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.